News
FDA grants priority review to spesolimab for pustular psoriasis.
Boehringer announced that the FDA has accepted a Biologics License Application and granted Priority Review for spesolimab for the treatment of generalized pustular psoriasis (GPP) flares.
FDA grants Priority Review to applications for medicines that, if approved, would offer significant improvement over available options in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions.
The FDA has granted spesolimab Orphan Drug Designation for the treatment of GPP, and Breakthrough Therapy Designation for spesolimab for the treatment of GPP flares in adults.
Condition: Psoriasis: Pustular
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.